Similarly, metformin, the first-line treatment for type 2 diabetes (T2D), has been reported to influence Nrf2 pathway activation through its effects on mitochondrial function and AMP-activated protein kinase (AMPK) signaling [120]. This evidence concerns the gene NFE2L2 and type 2 diabetes mellitus.